Phase 1 entrants seek improved safety
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.
Multi-specific antibodies and cell therapies enter phase 1
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
